Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces

被引:127
作者
Ferreira, Viviana P.
Herbert, Andrew P.
Hocking, Henry G.
Barlow, Paul N.
Pangburn, Michael K. [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Biochem, Ctr Biomed Res, Tyler, TX 75708 USA
[2] Univ Edinburgh, Edinburgh Biomol Nucl Magnet Resonance Unit, Edinburgh, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
D O I
10.4049/jimmunol.177.9.6308
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The plasma protein factor H primarily controls the activation of the alternative pathway of complement. The C-terminal of factor H is known to be involved in protection of host cells from complement attack. In the present study, we show that domains 19-20 alone are capable of discriminating between host-like and complement-activating cells. Furthermore, although factor H possesses three binding sites for C3b, binding to cell-bound C3b can be almost completely inhibited by the single site located in domains 19-20. All of the regulatory activities of factor H are expressed by the N-terminal four domains, but these activities toward cell-bound C3b are inhibited by isolated recombinant domains 19-20 (rH 19-20). Direct competition with the N-terminal site is unlikely to explain this because regulation of fluid phase C3b is unaffected by domains 19-20. Finally, we show that addition of isolated rH 19-20 to normal human serum leads to aggressive complement-mediated lysis of normally nonactivating sheep erythrocytes and moderate lysis of human erythrocytes, which possess membrane-bound regulators of complement. Taken together, the results highlight the importance of the cell surface protective functions exhibited by factor H compared with other complement regulatory proteins. The results may also explain why atypical hemolytic uremic syndrome patients with mutations affecting domains 19-20 can maintain complement homeostasis in plasma while their complement system attacks erythrocytes, platelets, endothelial cells, and kidney tissue.
引用
收藏
页码:6308 / 6316
页数:9
相关论文
共 70 条
[1]   LOCALIZATION OF THE COMPLEMENT-COMPONENT-C3B-BINDING SITE AND THE COFACTOR ACTIVITY FOR FACTOR-I IN THE 38KDA TRYPTIC FRAGMENT OF FACTOR-H [J].
ALSENZ, J ;
LAMBRIS, JD ;
SCHULZ, TF ;
DIERICH, MP .
BIOCHEMICAL JOURNAL, 1984, 224 (02) :389-398
[2]   Hemolytic uremic syndrome - An example of insufficient complement regulation on self-tissue [J].
Atkinson, JP ;
Liszewski, MK ;
Richards, A ;
Kavanagh, D ;
Moulton, EA .
NATURAL PRODUCTS AND MOLECULAR THERAPY, 2005, 1056 :144-152
[3]  
Blackmore TK, 1996, J IMMUNOL, V157, P5422
[4]  
Blackmore TK, 1998, J IMMUNOL, V160, P3342
[5]   Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome [J].
Buddles, MRH ;
Donne, RL ;
Richards, A ;
Goodship, J ;
Goodship, THJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (05) :1721-1722
[6]  
Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
[7]   Complement factor H as a marker for detection of bladder cancer [J].
Cheng, ZZ ;
Corey, MJ ;
Pärepalo, M ;
Majno, S ;
Hellwage, J ;
Zipfel, PF ;
Kinders, RJ ;
Raitanen, M ;
Meri, S ;
Jokiranta, TS .
CLINICAL CHEMISTRY, 2005, 51 (05) :856-863
[8]  
CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278
[9]   Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis [J].
Corey, MJ ;
Kinders, RJ ;
Poduje, CM ;
Bruce, CL ;
Rowley, H ;
Brown, LG ;
Hass, GM ;
Vessella, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (17) :12917-12925
[10]   The human complement factor H:: functional roles, genetic variations and disease associations [J].
de Córdoba, SR ;
Esparza-Gordillo, J ;
de Jorge, EG ;
Lopez-Trascasa, M ;
Sánchez-Corral, P .
MOLECULAR IMMUNOLOGY, 2004, 41 (04) :355-367